Simcere Pharmaceutical Group Limited (2096.HK) says it signs a research collaboration agreement with Stanford Medicine to advance an exploratory study in respiratory diseases. The agreement is dated May 29, 2026 (Pacific Time). Under the collaboration, the two organizations plan to work together on developing innovative therapeutic approaches for patients with idiopathic pulmonary fibrosis (IPF). The announcements describe the study as “exploratory” and focus on the respiratory field, with the goal of supporting future therapy development for people affected by IPF. The company’s communications emphasize the research cooperation rather than any specific drug, clinical phase, or timeline for results. No additional deal terms, funding amounts, participating investigators, or endpoints are provided in the supplied materials. The partnership is presented as an effort to combine Simcere’s research capabilities with Stanford Medicine’s expertise to identify potential new treatments for IPF patients.